Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Neurobiol Dis. 2017 Dec 5;110:122–132. doi: 10.1016/j.nbd.2017.11.017

Figure 4.

Figure 4

Endothelia nitric oxide synthase abrogated BLVRA benefits. Hemoglobin content was evaluated with eNOS inhibitor (iromycin A), iNOS inhibitor (MEG), and nNOS inhibitor (NPA) co-administered with BLVRA at 72 h after GMH (A). Co-localization of BLVRA (scale bar: 100 μm), mannose receptor and DAPI at 72 h after GMH (B) and quantified activated M2 microglia (C). The expression levels of BLVRA, CD206, and CD36 were measured by western blot assay (D–F). Western blots revealed expression of TLR4, IL-1β, IL-6 and TNF-α expression at 3 days after GMH in eNOS inhibitor group (G–K). Values are expressed as mean ± SD. *P < 0.05 compared with sham group, #P < 0.05 compared with sham group, &P < 0.05 compared with BLVRA. N = 6 each group.